Nearly everyone with multiple myeloma relapses. That doesn’t make it easy. A cancer diagnosis is traumatic, especially when the cancer is treatable, but not curable. In multiple myeloma, the disease ...

Peter Voorhees, MD, of Atrium Health Levine Cancer Institute, discusses data from the MonumenTAL-3 study (NCT05455320), a ...

When multiple myeloma returns after a period of remission, treatment plans often need to be adjusted because the cancer may have become resistant to previous medications. Doctors determine the most ...

Significant unmet need for patients requires new and novel treatments1 DREAMM-7 showed a 51% reduction in the risk of death and tripled median progression-free survival in 3L+ indicated population ...

Tecvayli plus Darzalex Faspro improved overall and progression-free survival in relapsed/refractory multiple myeloma compared to standard treatments. Tec-Dara showed a higher complete response rate ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this 12-part journey through a disease state ...

Rahul Banerjee, MD, discusses the most relevant multiple myeloma treatment options presented at the EHA Congress 2026.

A new clinical trial shows that TALVEY, an immunotherapy drug, works even better when given to myeloma patients earlier.

The National Comprehensive Cancer Network provides a list of preferred primary therapy regimens for transplant-eligible and nontransplant candidates and lists drugs recommended for maintenance therapy ...

Johnson & Johnson JNJ announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use ...

The National Institute for Health and Care Excellence (NICE) has recommended that belantamab mafodotin (Blenrep, GSK) be made available on the NHS for people in England with multiple myeloma that has ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. The good news, I guess, is that we have ...